You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大藥廠(00950.HK)回升5.5%曾高見6.22元 富瑞首予「買入」評級
阿思達克 07-22 15:17
上周五表示附屬治療官頸癌藥物已向國家藥監局提交認定申請的李氏大藥廠(00950.HK)今天獲富瑞金融首予「買入」評級,該股回吐守穩10天線,今天逆市曾彈7.4%高見6.22元,現造6.11元,回升5.5%,成交增至318萬股,涉資1,924萬元。

大摩上周二將李氏大藥廠評級由「與大市同步」升至「增持」,目標價上調60%至8元,同時將2021-2022年盈測上調4%-5%。報告指,集團在研產品線豐富將推動2021年及之後業績增長,料未來12個月或有超過10種藥物獲批,且更多藥物已進入關鍵性試驗,加上已宣布考慮分拆眼科藥品開發業務COPFL上市,有望釋放價值。該股當日曾升至6.75元逼近五個月高遇壓。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account